论文部分内容阅读
目的探讨内质网蛋白29(ERp29)在乳腺癌中的表达及其临床意义。方法通过免疫组化SP二步法检测乳腺癌组织中ERp29的表达情况,并分析ERp29与临床病理特征和无病生存期(DFS)等的关系。结果共收集71例患者的乳腺癌组织标本,42例ERp29表达阳性,阳性表达率为59.15%,ERp29表达与患者的TNM分期、肿块直径存在统计学关联,但未见与患者年龄、病理分级、淋巴结转移及激素受体表达、原癌基因人类表皮生长因子受体2(HER-2)表达和辅助治疗等因素间存在统计学关联。ERp29表达阳性患者3年DFS高于阴性患者。Cox回归分析显示TNM分期(包括肿块直径和淋巴结转移)是影响乳腺癌患者预后的因素(OR=34.218,95%CI:7.828~149.566,P<0.05)。结论乳腺癌组织ERp29表达与肿瘤的病理特征及预后相关,但ERp29是否为与预后相关的潜在抑癌基因,有待更多方面作进一步验证。
Objective To investigate the expression of endoplasmic reticulum protein 29 (ERp29) in breast cancer and its clinical significance. Methods The expression of ERp29 in breast cancer tissues was detected by immunohistochemical SP method and the relationship between ERp29 and clinical pathological features and disease-free survival (DFS) was analyzed. Results A total of 71 cases of breast cancer tissue samples were collected, 42 cases of ERp29 expression was positive, the positive rate was 59.15%. The expression of ERp29 was correlated with TNM stage and tumor diameter, but no correlation was found between age, Lymph node metastasis and hormone receptor expression, proto-oncogene human epidermal growth factor receptor 2 (HER-2) expression and adjuvant therapy and other factors between the statistical correlation. Patients with positive ERp29 expression had a higher 3-year DFS than negative patients. Cox regression analysis showed that TNM stage (including tumor diameter and lymph node metastasis) were the factors affecting the prognosis of patients with breast cancer (OR = 34.218, 95% CI: 7.828-149.566, P <0.05). Conclusion The expression of ERp29 in breast cancer is related to the pathological features and prognosis of breast cancer. However, whether ERp29 is a potential tumor suppressor gene associated with prognosis needs to be further verified in more aspects.